Results 131 to 140 of about 20,923 (159)
Some of the next articles are maybe not open access.
Gériatrie et Psychologie Neuropsychiatrie du Viellissement, 2021
Glucose and sodium tubular reabsorption inhibitors, or gliflozins, are a new therapeutic class. Their novel mechanism of action involves inhibition of a glucose and Na+ reabsorption co-transporter in the renal proximal tubule. They reduce blood glucose levels by reducing renal glucose reabsorption.
Gilles, Berrut +5 more
openaire +3 more sources
Glucose and sodium tubular reabsorption inhibitors, or gliflozins, are a new therapeutic class. Their novel mechanism of action involves inhibition of a glucose and Na+ reabsorption co-transporter in the renal proximal tubule. They reduce blood glucose levels by reducing renal glucose reabsorption.
Gilles, Berrut +5 more
openaire +3 more sources
Empagliflozin directly improves diastolic function in human heart failure
European Journal of Heart Failure, 2018 Aims Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodium-dependent glucose co-transporter 2, has recently been evaluated for its cardiovascular safety.
Katrin Streckfuss-Bömeke +1 more
exaly +2 more sources
Assay of Empagliflozin in Empagliflozin Tablets by HPLC
International Journal of Drug Delivery TechnologyBackground: Empagliflozin is a member of the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, which helps lower blood glucose levels by promoting the excretion of glucose through urine. It is indicated for type 2 diabetes and is not suitable for managing type 1 diabetes, where insulin production is absent.
Dr. Parag Das +6 more
openaire +1 more source